BEL114333, a Multicenter, Continuation Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase III Study BEL113750 in Northeast Asia or Completed the Open-label Extension of HGS1006-C1115 in Japan
Latest Information Update: 07 Jun 2022
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 05 Jun 2021 Results of meta-analysis of 6 studies (110752, 110751, LBSL02 [safety only], 112341, 113750, and 115471) assessing safety and efficacy of belimumab in older adults with SLE, presented at the 22nd Annual Congress of the European League Against Rheumatism.
- 06 Jun 2020 Results assessing long-term efficacy and safety presented at the 21st Annual Congress of the European League Against Rheumatism
- 20 Sep 2018 Status changed from active, no longer recruiting to completed.